# DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Source: https://onco.cc/trials/nct06805305/  
OnCo record `nct06805305` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Diakonos Oncology Corporation, now recruiting.

## Summary

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) is a phase 2 interventional study registered as NCT06805305 by Diakonos Oncology Corporation, with 180 participants planned, started 2025-03-17 and due to reach its primary completion in 2030-03. Interventions recorded: DOC1021, Tumor resection, Temodar (Temozolomide) and SOC cranial radiation.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06805305
- Phase: 2
- Setting: Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination With Standard of Care for Newly Diagnosed Adult Glioblastoma
- Sponsor: Diakonos Oncology Corporation
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06805305: https://clinicaltrials.gov/study/NCT06805305

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [DOC1021](https://onco.cc/drugs/doc1021/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Diakonos Oncology](https://onco.cc/companies/diakonos-oncology/)

---
JSON: https://onco.cc/api/v1/entities/nct06805305.json